Sera Prognostics, Inc. Overview
Pro stress-test →Sera Prognostics is a women's health diagnostic company that discovers, develops, and commercializes blood-based biomarker tests for pregnancy complications. The company's flagship product, the PreTRM test, is the only FDA-validated blood test to predict preterm birth risk, addressing a critical unmet need in prenatal care affecting millions of pregnancies annually.
Strategic Profile
Pro stress-test →Sera leverages proprietary proteomics and bioinformatics platforms to build a pipeline of pregnancy-related biomarker tests including preeclampsia, fetal growth restriction, and gestational diabetes detection. The company is pursuing payer adoption through Medicaid pilots across multiple states while scaling from early commercialization toward market penetration in precision pregnancy care.
Competitive Landscape
Pro stress-test →Sera competes in the pregnancy diagnostics and women's health biomarker space against companies like Biodesix, BioGenex, GRAIL, and other diagnostic developers. Sera's differentiation centers on the PreTRM test's clinical validation and first-mover advantage in preterm birth prediction, though broader adoption requires successful Medicaid reimbursement and clinical integration into standard prenatal care protocols.
Industry Context
Sera Prognostics, Inc. operates in Women's Health Diagnostics / Precision Pregnancy Care / In Vitro Diagnostics (IVD).
Key facts
Founded: 2008 · Headquarters: Salt Lake City, Utah · Revenue: $95K (TTM as of Sept 2025) · Market cap: $144.6M